Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Peripheral blood stem cells

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    280 result(s) found for: Peripheral blood stem cells. Displaying page 1 of 14.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2006-006146-34 Sponsor Protocol Number: 100505 Start Date*: 2008-04-30
    Sponsor Name:Stage Pharmaceuticals GmbH
    Full Title: Adoptive Immunotherapy of chemotherapy refractory CMV infections using Streptamer-isolated T cells after allogeneic bone marrow or peripheral blood stem cell transplantation: a phase I/II trial
    Medical condition: -chronic persistent CMV infection after allogeneic bone marrow or peripheral blood stem cell transplantation, refractory to antiviral chemotherapy
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-003362-84 Sponsor Protocol Number: FSJD-DIPG-DC Start Date*: 2016-05-18
    Sponsor Name:Fundació Sant Joan de Déu
    Full Title: Phase Ib clinical trial on the safety of immunotherapy with autologous dendritic cells primed with lysate allogeneic tumor lines in patients with diffuse intrinsic pontine glioma ( DIPG )
    Medical condition: Diffuse intrinsic pontine glioma (DIPG)
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006143 Brain stem glioma PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005562-38 Sponsor Protocol Number: M2011-238 Start Date*: 2012-11-13
    Sponsor Name:Miltenyi Biotec GmbH
    Full Title: A multi-center phase I/II safety and feasibility study using CliniMACS TCRα/β and CD19 depleted stem cell grafts from haploidentical donors for haematopoietic progenitor cell transplantation in chi...
    Medical condition: Hematological and non-hematological malignancies, and non-malignant diseases, requiring allogeneic blood stem cell transplantation without available HLA-identical donor.
    Disease: Version SOC Term Classification Code Term Level
    18.1 10042613 - Surgical and medical procedures 10063581 Stem cell transplant PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-002210-36 Sponsor Protocol Number: PR2006-03 Start Date*: 2006-11-10
    Sponsor Name:Queen Mary University of London
    Full Title: A Phase II study evaluating intravenous Melphalan with autologous whole blood stem cell transplantation (PBSCT) in patients with Androgen –Independent Prostate Cancer (AIPC)
    Medical condition: Open-labelled, non-randomised, treatment intensifying cohort study in androgen-independent prostate cancer (AIPC.)
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001476-63 Sponsor Protocol Number: 2014-001476-63 Start Date*: 2023-05-05
    Sponsor Name:CELLPROTHERA S.A.S
    Full Title: A multicentric controlled phase I / IIb study evaluating the safety and the efficacy of in vitro expanded peripheral blood CD34+ stem cells output by the StemXpand® Automated Process, and injected ...
    Medical condition: Severe acute myocardial Infarction. Indication : Injection of in vitro expanded peripheral blood CD34+ stem cells output by the StempXpand Automated Process, in patients with an acute myocardial in...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-024307-27 Sponsor Protocol Number: LUMC2010-03 Start Date*: 2011-11-01
    Sponsor Name:Leiden University Medical Center
    Full Title: TREATMENT WITH CMV PP65-SPECIFIC T CELLS GENERATED BY USE OF A CMV PP65 PROTEIN-SPANNING PEPTIDE POOL IN PATIENTS WITH CMV REACTIVATION OR CMV DISEASE AFTER ALLOGENEIC STEM CELL TRANSPLANTATION
    Medical condition: CMV reactivation after allogeneic stem cell transplantation
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-023436-16 Sponsor Protocol Number: HOVON 107 Start Date*: 2011-05-31
    Sponsor Name:HOVON Foundation
    Full Title: The feasibility and efficacy of subcutaneous and intravenous Plerixafor for mobilization of peripheral blood stem cells in allogeneic HLA–identical sibling donors: a randomized phase II study.
    Medical condition: stem cell mobilization
    Disease: Version SOC Term Classification Code Term Level
    12.1 10053948 Hematopoietic stem cell mobilization LLT
    12.1 10024329 Leukemia LLT
    12.1 10028533 Myelodysplastic syndrome LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing) DE (Restarted)
    Trial results: View results
    EudraCT Number: 2008-003185-26 Sponsor Protocol Number: CIK 2 Start Date*: 2009-04-14
    Sponsor Name:AZIENDA OSPEDALIERA "OSPEDALI RIUNITI DI BERGAMO" (A.O. DI RILIEVO NAZIONALE)
    Full Title: Sequential Infusion of Unmanipulated Donor Lymphocytes and Cytokine Induced Killer (CIK) cells after allogeneic stem cell transplantation
    Medical condition:  Patients with haematologic malignancies (excluding CML)
    Disease: Version SOC Term Classification Code Term Level
    9.1 10005329 Blood and lymphatic system disorders SOC
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-002879-34 Sponsor Protocol Number: PSCT16 Start Date*: 2013-03-05
    Sponsor Name:Radboud University Nijmegen Medical Centre
    Full Title: Vaccination with minor histocompatibility antigen-loaded donor DC vaccines to boost graft-versus-tumor immunity after allogeneic stem cell transplantation
    Medical condition: Patients with aggressive hematological malignancies treated with allogeneic stem cell transplantation
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2021-003607-17 Sponsor Protocol Number: Rasmusscell Start Date*: 2023-01-12
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario de La Princesa
    Full Title: Phase I, open-label clinical trial to evaluate the safety and clinical response of repeated-dose intra-arterial infusion of autologous mesenchymal cells in children and adolescents with refractory ...
    Medical condition: Autoimmune refractory epilepsy and Rasmussen Encephalitis
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004545-18 Sponsor Protocol Number: NA Start Date*: 2005-04-26
    Sponsor Name:CHU Sart Tilman
    Full Title: Cell therapy for cardiac repair through mobilization of hematopoietic stem cells and endothelial progenitors in patients with chronic ischemic cardiomyopathy.
    Medical condition: Chronic ischemic cardiac disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2013-004953-26 Sponsor Protocol Number: BHS-TC13 Start Date*: 2016-03-11
    Sponsor Name:Ghent University Hospital
    Full Title: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Medical condition: CMV specific T cell therapy for the treatment of relapsing or therapy refractory CMV infection after allogeneic stem cell transplantation with a CMV-positive donor.
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004590-24 Sponsor Protocol Number: 1949 Start Date*: 2005-10-10
    Sponsor Name:AZIENDA SANITARIA OSPEDALIERA S. GIOVANNI BATTISTA DI TORINO
    Full Title: PHASE II PILOT PROTOCOL OF BONEMARROW STAM CELLS MOBILIZATION BY CYTOCHINE STIMULATION IN PATIENTS WITH COMPLEX ANAL FISTULAS AND/OR RECURRENCES AND/OR ANAL-PERIANAL LOCALIZATIONS OF IBD
    Medical condition: PATIENTS WITH COMPLEX ANAL FISTULAS AND/OR RECURRENCES AND/OR ANAL-PERIANAL LOCALIZATIONS OF IBD
    Disease: Version SOC Term Classification Code Term Level
    6.1 10002644 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2006-004101-26 Sponsor Protocol Number: TJB0601P1 Start Date*: 2006-12-13
    Sponsor Name:CHU Sart-Tilman
    Full Title: Mesenchymal stem cell infusion as prevention for graft rejection and graft-versus-host disease after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning: a pilot study
    Medical condition: Patients with hematological malignancies not candidate for conventional allogeneic transplantation because of age or comorbidities.
    Disease: Version SOC Term Classification Code Term Level
    8.1 10027703 Mismatched donor bone marrow transplantation therapy LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-011152-22 Sponsor Protocol Number: GTG003.08 Start Date*: Information not available in EudraCT
    Sponsor Name:GENETHON
    Full Title: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome
    Medical condition: Phase 1/2 clinical trial of haematopoietic stem cell gene therapy for the Wiskott-Aldrich Syndrome. An open labelled, non-randomised, phase I/II, cohort study involving a single infusion of autolo...
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2008-003537-25 Sponsor Protocol Number: 04032008 Start Date*: 2008-08-28
    Sponsor Name:University Medical Center Groningen
    Full Title: Can the steady-state hematopoiesis be improved post-ASCT by infusion of the autologous stem cell transplant directly in the bone marrow compartment.
    Medical condition: Study population - patient age 18-65 years - eligible for an ASCT for lymphoma or MM - at least ≥ 10 x 106 CD34+ cells/kg have been collected during the previous performed leucofereses procedure
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-004240-30 Sponsor Protocol Number: AIT-MULTIVIR-01 Start Date*: 2014-06-18
    Sponsor Name:Universitätsklinikum Erlangen
    Full Title: Prospective, open-label, randomised, two-arm, controlled, multicentre clinical trial, phase I/IIa, for the evaluation of safety and efficacy of an adoptive immunotherapy with allogeneic CMV-/EBV-sp...
    Medical condition: Immune deficiency after allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021428 - Immune system disorders 10007877 Cell-mediated immune deficiency PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-001335-31 Sponsor Protocol Number: virus-specific_CD8_T-cells_001 Start Date*: 2013-11-08
    Sponsor Name:Univerzita Karlova v Praze, 2. lékařská fakulta
    Full Title: Adoptive transfer of CMV specific CD8+ T-cells to treat CMV infection after transplantation
    Medical condition: chronic CMV infection after allogeneic hematopoietic stem cell transplantation in children, refractory to conventional antiviral treatment
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006649-18 Sponsor Protocol Number: 08/0214 Start Date*: 2011-11-16
    Sponsor Name:University College London
    Full Title: CMV TCR Gene Therapy: A Phase I Safety, Toxicity and Feasibility Study of Adoptive Immunotherapy with CMV TCR-transduced Donor-derived T cells for Recipients of Allogeneic Haematopoietic Stem Cell ...
    Medical condition: CMV reactivation/infection in post allogeneic haematopoietic stem cell transplant recipients. Allo-HSCT being performed for underlying haematological malignancy (eg, AML, ALL, NHL, Hodgkin Lymphoma...
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10067859 Allogenic stem cell transplantation LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-002343-14 Sponsor Protocol Number: RAG1-2019-01 Start Date*: 2020-09-25
    Sponsor Name:Leiden University Medical Center
    Full Title: PHASE I/II CLINICAL TRIAL OF AUTOLOGOUS HEMATOPOIETIC STEM CELL GENE THERAPY FOR RAG1-DEFICIENT SEVERE COMBINED IMMUNODEFICIENCY
    Medical condition: Patients with severe combined immunodeficiency (SCID) based on a genetic defect in the Recombinase Activating Gene 1 (RAG1)
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: NL (Trial now transitioned) ES (Ongoing) PL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun Jun 01 08:48:31 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA